An asthmatic case of psoriasiform eruption caused by administration of dupilumab
Dear Editor, Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor alpha chain and inhibits type 2 inflammation. It is suitable for atopic dermatitis and asthma therapy and injected subcutaneously every two weeks. Some side effects reported to date are injection site react...
Gespeichert in:
| Veröffentlicht in: | Allergology International 2020-07, Vol.69 (3), p.478-479 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 479 |
|---|---|
| container_issue | 3 |
| container_start_page | 478 |
| container_title | Allergology International |
| container_volume | 69 |
| creator | Matsuda, Takashi Yamada, Hideyasu Hida, Norihito Nakaizumi, Taisuke Yamada, Emmi Satoh, Hiroaki Hizawa, Nobuyuki |
| description | Dear Editor, Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor alpha chain and inhibits type 2 inflammation. It is suitable for atopic dermatitis and asthma therapy and injected subcutaneously every two weeks. Some side effects reported to date are injection site reactions, conjunctivitis, and rarely anaphylaxis. Here, we present a patient with severe asthma who experienced the onset of psoriasis after treatment with dupilumab. Details of this case from the viewpoint of mechanisms connecting dupilumab and the pathophysiology of psoriasis are given. He gave us written informed consent for publication of this case report. A 60-year-old man had been diagnosed with asthma and treated with an inhalation therapy of inhaled corticosteroids (ICS), long-acting beta agonist (LABA), and long-acting muscarinic antagonist (LAMA) for 6 years at our hospital. |
| doi_str_mv | 10.1016/j.alit.2020.02.004 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmed_primary_32178985</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1323893020300162</els_id><doaj_id>oai_doaj_org_article_47cbc7f0dac0439b89f1f99e6487c7bb</doaj_id><sourcerecordid>S1323893020300162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c732t-23e12e52305729c7fecd0c9419562caf5424ae350fcdbbc1877584553c2049693</originalsourceid><addsrcrecordid>eNqNUcFu1TAQjBCIlsIPcEC5ozzWazuOJS7VUymVKsEBzpbtOOAoiSM7oerf47y074i42CvvzHh2tijeEzgQIPWn_qAHvxwQEA6ABwD2orgkjEFFuMSXuaZIq0ZSuCjepNQDEBRSvC4uKBLRyIZfFt-vp1Kn5feoF29Lq5MrQ1fOKUSvk-9CHEsX13nxYcrdNbm2NI-lbkc_-bREfWpkRrvOflhHbd4Wrzo9JPfu6b4qfn65-XH8Wt1_u707Xt9XVlBcKqSOoONIgQuUVnTOtmAlI5LXaHXHGTLtKIfOtsZY0gjBG8Y5tQhM1pJeFXe7bht0r-boRx0fVdBenR5C_KV0zDMNTjFhTf4BWm2BUWka2ZFOSlezRlhhTNbCXcvGkFJ03VmPgNqiVr3aolZb1ApQ5agz6cNOmlczuvZMec42Az7ugAdnQpesd5N1ZxgA1CAkIMsVbujm_9FHv5ySP4Z1WjL1dqdmG97qIUyDn5zqwxqnvAJlH1h2Pz3bh1oCzVNwBUw02yEpFzVBzEqfdyWXN_fHu6iejLQ-OrvkaP2_IvkLqaTGsQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>An asthmatic case of psoriasiform eruption caused by administration of dupilumab</title><source>J-STAGE Free</source><source>Freely Accessible Japanese Titles</source><source>DOAJ Directory of Open Access Journals</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Matsuda, Takashi ; Yamada, Hideyasu ; Hida, Norihito ; Nakaizumi, Taisuke ; Yamada, Emmi ; Satoh, Hiroaki ; Hizawa, Nobuyuki</creator><creatorcontrib>Matsuda, Takashi ; Yamada, Hideyasu ; Hida, Norihito ; Nakaizumi, Taisuke ; Yamada, Emmi ; Satoh, Hiroaki ; Hizawa, Nobuyuki ; Faculty of Medicine ; cDivision of Dermatological Medicine ; Hitachi Hitachinaka General Hospital ; dDivision of Respiratory Medicine ; aDivision of Respiratory Medicine ; bDivision of Respiratory Medicine ; Mito Medical Center ; University of Tsukuba</creatorcontrib><description>Dear Editor, Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor alpha chain and inhibits type 2 inflammation. It is suitable for atopic dermatitis and asthma therapy and injected subcutaneously every two weeks. Some side effects reported to date are injection site reactions, conjunctivitis, and rarely anaphylaxis. Here, we present a patient with severe asthma who experienced the onset of psoriasis after treatment with dupilumab. Details of this case from the viewpoint of mechanisms connecting dupilumab and the pathophysiology of psoriasis are given. He gave us written informed consent for publication of this case report. A 60-year-old man had been diagnosed with asthma and treated with an inhalation therapy of inhaled corticosteroids (ICS), long-acting beta agonist (LABA), and long-acting muscarinic antagonist (LAMA) for 6 years at our hospital.</description><identifier>ISSN: 1323-8930</identifier><identifier>EISSN: 1440-1592</identifier><identifier>DOI: 10.1016/j.alit.2020.02.004</identifier><identifier>PMID: 32178985</identifier><language>eng</language><publisher>TOKYO: Elsevier B.V</publisher><subject>Allergy ; Immunology ; Life Sciences & Biomedicine ; Science & Technology</subject><ispartof>Allergology International, 2020-07, Vol.69 (3), p.478-479</ispartof><rights>2020 Japanese Society of Allergology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>5</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000607902400025</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c732t-23e12e52305729c7fecd0c9419562caf5424ae350fcdbbc1877584553c2049693</citedby><cites>FETCH-LOGICAL-c732t-23e12e52305729c7fecd0c9419562caf5424ae350fcdbbc1877584553c2049693</cites><orcidid>0000-0002-5489-2062</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,866,2106,2118,27933,27934,28257</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32178985$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsuda, Takashi</creatorcontrib><creatorcontrib>Yamada, Hideyasu</creatorcontrib><creatorcontrib>Hida, Norihito</creatorcontrib><creatorcontrib>Nakaizumi, Taisuke</creatorcontrib><creatorcontrib>Yamada, Emmi</creatorcontrib><creatorcontrib>Satoh, Hiroaki</creatorcontrib><creatorcontrib>Hizawa, Nobuyuki</creatorcontrib><creatorcontrib>Faculty of Medicine</creatorcontrib><creatorcontrib>cDivision of Dermatological Medicine</creatorcontrib><creatorcontrib>Hitachi Hitachinaka General Hospital</creatorcontrib><creatorcontrib>dDivision of Respiratory Medicine</creatorcontrib><creatorcontrib>aDivision of Respiratory Medicine</creatorcontrib><creatorcontrib>bDivision of Respiratory Medicine</creatorcontrib><creatorcontrib>Mito Medical Center</creatorcontrib><creatorcontrib>University of Tsukuba</creatorcontrib><title>An asthmatic case of psoriasiform eruption caused by administration of dupilumab</title><title>Allergology International</title><addtitle>ALLERGOL INT</addtitle><addtitle>Allergol Int</addtitle><description>Dear Editor, Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor alpha chain and inhibits type 2 inflammation. It is suitable for atopic dermatitis and asthma therapy and injected subcutaneously every two weeks. Some side effects reported to date are injection site reactions, conjunctivitis, and rarely anaphylaxis. Here, we present a patient with severe asthma who experienced the onset of psoriasis after treatment with dupilumab. Details of this case from the viewpoint of mechanisms connecting dupilumab and the pathophysiology of psoriasis are given. He gave us written informed consent for publication of this case report. A 60-year-old man had been diagnosed with asthma and treated with an inhalation therapy of inhaled corticosteroids (ICS), long-acting beta agonist (LABA), and long-acting muscarinic antagonist (LAMA) for 6 years at our hospital.</description><subject>Allergy</subject><subject>Immunology</subject><subject>Life Sciences & Biomedicine</subject><subject>Science & Technology</subject><issn>1323-8930</issn><issn>1440-1592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>DOA</sourceid><recordid>eNqNUcFu1TAQjBCIlsIPcEC5ozzWazuOJS7VUymVKsEBzpbtOOAoiSM7oerf47y074i42CvvzHh2tijeEzgQIPWn_qAHvxwQEA6ABwD2orgkjEFFuMSXuaZIq0ZSuCjepNQDEBRSvC4uKBLRyIZfFt-vp1Kn5feoF29Lq5MrQ1fOKUSvk-9CHEsX13nxYcrdNbm2NI-lbkc_-bREfWpkRrvOflhHbd4Wrzo9JPfu6b4qfn65-XH8Wt1_u707Xt9XVlBcKqSOoONIgQuUVnTOtmAlI5LXaHXHGTLtKIfOtsZY0gjBG8Y5tQhM1pJeFXe7bht0r-boRx0fVdBenR5C_KV0zDMNTjFhTf4BWm2BUWka2ZFOSlezRlhhTNbCXcvGkFJ03VmPgNqiVr3aolZb1ApQ5agz6cNOmlczuvZMec42Az7ugAdnQpesd5N1ZxgA1CAkIMsVbujm_9FHv5ySP4Z1WjL1dqdmG97qIUyDn5zqwxqnvAJlH1h2Pz3bh1oCzVNwBUw02yEpFzVBzEqfdyWXN_fHu6iejLQ-OrvkaP2_IvkLqaTGsQ</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Matsuda, Takashi</creator><creator>Yamada, Hideyasu</creator><creator>Hida, Norihito</creator><creator>Nakaizumi, Taisuke</creator><creator>Yamada, Emmi</creator><creator>Satoh, Hiroaki</creator><creator>Hizawa, Nobuyuki</creator><general>Elsevier B.V</general><general>JAPANESE SOCIETY OF ALLERGOLOGY</general><general>Japanese Society Allergology</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-5489-2062</orcidid></search><sort><creationdate>20200701</creationdate><title>An asthmatic case of psoriasiform eruption caused by administration of dupilumab</title><author>Matsuda, Takashi ; Yamada, Hideyasu ; Hida, Norihito ; Nakaizumi, Taisuke ; Yamada, Emmi ; Satoh, Hiroaki ; Hizawa, Nobuyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c732t-23e12e52305729c7fecd0c9419562caf5424ae350fcdbbc1877584553c2049693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Allergy</topic><topic>Immunology</topic><topic>Life Sciences & Biomedicine</topic><topic>Science & Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsuda, Takashi</creatorcontrib><creatorcontrib>Yamada, Hideyasu</creatorcontrib><creatorcontrib>Hida, Norihito</creatorcontrib><creatorcontrib>Nakaizumi, Taisuke</creatorcontrib><creatorcontrib>Yamada, Emmi</creatorcontrib><creatorcontrib>Satoh, Hiroaki</creatorcontrib><creatorcontrib>Hizawa, Nobuyuki</creatorcontrib><creatorcontrib>Faculty of Medicine</creatorcontrib><creatorcontrib>cDivision of Dermatological Medicine</creatorcontrib><creatorcontrib>Hitachi Hitachinaka General Hospital</creatorcontrib><creatorcontrib>dDivision of Respiratory Medicine</creatorcontrib><creatorcontrib>aDivision of Respiratory Medicine</creatorcontrib><creatorcontrib>bDivision of Respiratory Medicine</creatorcontrib><creatorcontrib>Mito Medical Center</creatorcontrib><creatorcontrib>University of Tsukuba</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Allergology International</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsuda, Takashi</au><au>Yamada, Hideyasu</au><au>Hida, Norihito</au><au>Nakaizumi, Taisuke</au><au>Yamada, Emmi</au><au>Satoh, Hiroaki</au><au>Hizawa, Nobuyuki</au><aucorp>Faculty of Medicine</aucorp><aucorp>cDivision of Dermatological Medicine</aucorp><aucorp>Hitachi Hitachinaka General Hospital</aucorp><aucorp>dDivision of Respiratory Medicine</aucorp><aucorp>aDivision of Respiratory Medicine</aucorp><aucorp>bDivision of Respiratory Medicine</aucorp><aucorp>Mito Medical Center</aucorp><aucorp>University of Tsukuba</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An asthmatic case of psoriasiform eruption caused by administration of dupilumab</atitle><jtitle>Allergology International</jtitle><stitle>ALLERGOL INT</stitle><addtitle>Allergol Int</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>69</volume><issue>3</issue><spage>478</spage><epage>479</epage><pages>478-479</pages><issn>1323-8930</issn><eissn>1440-1592</eissn><abstract>Dear Editor, Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor alpha chain and inhibits type 2 inflammation. It is suitable for atopic dermatitis and asthma therapy and injected subcutaneously every two weeks. Some side effects reported to date are injection site reactions, conjunctivitis, and rarely anaphylaxis. Here, we present a patient with severe asthma who experienced the onset of psoriasis after treatment with dupilumab. Details of this case from the viewpoint of mechanisms connecting dupilumab and the pathophysiology of psoriasis are given. He gave us written informed consent for publication of this case report. A 60-year-old man had been diagnosed with asthma and treated with an inhalation therapy of inhaled corticosteroids (ICS), long-acting beta agonist (LABA), and long-acting muscarinic antagonist (LAMA) for 6 years at our hospital.</abstract><cop>TOKYO</cop><pub>Elsevier B.V</pub><pmid>32178985</pmid><doi>10.1016/j.alit.2020.02.004</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-5489-2062</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1323-8930 |
| ispartof | Allergology International, 2020-07, Vol.69 (3), p.478-479 |
| issn | 1323-8930 1440-1592 |
| language | eng |
| recordid | cdi_pubmed_primary_32178985 |
| source | J-STAGE Free; Freely Accessible Japanese Titles; DOAJ Directory of Open Access Journals; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Allergy Immunology Life Sciences & Biomedicine Science & Technology |
| title | An asthmatic case of psoriasiform eruption caused by administration of dupilumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-01T06%3A01%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20asthmatic%20case%20of%20psoriasiform%20eruption%20caused%20by%20administration%20of%20dupilumab&rft.jtitle=Allergology%20International&rft.au=Matsuda,%20Takashi&rft.aucorp=Faculty%20of%20Medicine&rft.date=2020-07-01&rft.volume=69&rft.issue=3&rft.spage=478&rft.epage=479&rft.pages=478-479&rft.issn=1323-8930&rft.eissn=1440-1592&rft_id=info:doi/10.1016/j.alit.2020.02.004&rft_dat=%3Celsevier_pubme%3ES1323893020300162%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32178985&rft_els_id=S1323893020300162&rft_doaj_id=oai_doaj_org_article_47cbc7f0dac0439b89f1f99e6487c7bb&rfr_iscdi=true |